CVS Health (NYSE:CVS) Posts Quarterly Earnings Results, Beats Estimates By $0.71 EPS

CVS Health (NYSE:CVS) issued its quarterly earnings results on Wednesday. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71, FiscalAI reports. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. During the same period in the prior year, the firm earned $1.81 earnings per share. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health updated its FY 2026 guidance to 7.900-8.100 EPS.

Here are the key takeaways from CVS Health’s conference call:

• CVS raised its 2026 outlook after a strong quarter, increasing adjusted EPS guidance by $0.60 to $7.90–$8.10 and raising operating cash-flow expectations to at least $11.5 billion.
• Second-quarter performance was broad-based: revenue rose more than 7% to over $106 billion, adjusted operating income increased 35% to approximately $5.2 billion, and adjusted EPS grew over 40% to $2.58. All operating segments reported year-over-year earnings growth.
• Aetna’s margin recovery is progressing faster than expected, with more than $2 billion of year-to-date adjusted operating-income improvement; management cited disciplined pricing, medical-cost management, and favorable Medicare performance.
• Management sees growing opportunities in GLP-1s through formulary management, cash-pay offerings, MinuteClinic weight-management visits, and manufacturer partnerships with Lilly and Novo. The company plans to reduce the virtual weight-management visit price to $29 and expand same-day pharmacy access.
• CVS expects 2027 headwinds from continued pressure in its 340B business and lower Caremark membership, partly due to more selective contracting and health-plan product exits. Management said these pressures should be offset over time by specialty pharmacy growth, generic savings, and broader enterprise momentum.

CVS Health Price Performance

NYSE:CVS traded down $0.61 during trading hours on Friday, hitting $95.61. 2,615,121 shares of the stock traded hands, compared to its average volume of 8,434,127. The company has a market cap of $121.99 billion, a price-to-earnings ratio of 25.24, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. CVS Health has a 1 year low of $63.30 and a 1 year high of $110.68. The stock has a 50 day moving average price of $102.17 and a 200 day moving average price of $87.68. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were paid a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Strong Q2 results: Revenue rose 7.3% year over year to $106.1 billion, while adjusted EPS of $2.58 exceeded the $1.87 consensus estimate. Net income nearly tripled to approximately $3 billion, supported by lower-than-expected medical costs, improved pharmacy profitability and stronger performance at Aetna. CVS raises guidance as it posts nearly $3B in profit, $106B in revenue for Q2
• Positive Sentiment: Guidance and cash flow raised: CVS lifted its 2026 adjusted EPS outlook to $7.90–$8.10 and forecast at least $11.5 billion in operating cash flow, reflecting confidence in Aetna’s Medicare Advantage recovery and continued retail strength. CVS forecasts at least $11.5B in 2026 operating cash flow
• Positive Sentiment: GLP-1 opportunity expanded: A new collaboration with Eli Lilly broadens CVS’s weight-management offering and could create additional value by combining its pharmacy, insurance and care-delivery capabilities. CVS posts sharply improved Q2, details GLP-1 market share plan
• Neutral Sentiment: Valuation view improved: One analyst fair-value estimate increased from $111.92 to $114.88, suggesting constructive longer-term sentiment, although execution and healthcare-policy risks remain. CVS Health stock gets fair value bump
• Negative Sentiment: PBM concerns overshadowed the beat: Management expects Caremark membership declines in 2026, while 340B-related pressure is expected to persist into 2027. These comments raised concerns about future revenue and profit durability, prompting the post-earnings retreat despite the guidance increase. CVS Q2 earnings call pairs Aetna recovery with 2027 PBM risks

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CVS shares. Piper Sandler restated an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a research note on Monday, June 1st. Sanford C. Bernstein raised their price target on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research report on Tuesday, May 12th. Truist Financial increased their target price on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Barclays lifted their target price on CVS Health from $106.00 to $108.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, UBS Group upped their price target on CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a report on Thursday. Twenty-two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $106.46.

Insider Activity at CVS Health

In related news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 3,372,000 shares of company stock worth $317,473,598. 0.85% of the stock is owned by company insiders.

Hedge Funds Weigh In On CVS Health

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP lifted its stake in shares of CVS Health by 193.2% during the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after acquiring an additional 12,233,675 shares during the last quarter. Amundi boosted its holdings in shares of CVS Health by 95.3% in the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after purchasing an additional 3,637,943 shares during the period. Morgan Stanley lifted its holdings in shares of CVS Health by 6.3% in the 4th quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock worth $1,616,863,000 after buying an additional 1,211,631 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of CVS Health by 148.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,467,170 shares of the pharmacy operator’s stock valued at $110,610,000 after buying an additional 876,443 shares during the period. Finally, Maple Rock Capital Partners Inc. purchased a new stake in CVS Health in the fourth quarter worth about $64,790,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.